Clinical experience with sorbinil--an aldose reductase inhibitor.
A considerable volume of animal pharmacologic data support the view that increased flux through the polyol pathway provides a unifying hypothesis for the major complications of diabetes. An extensive clinical program has been established to verify the extrapolation of the animal pharmacologic findings to man. Clinical data accumulated to date confirm the biochemical and electrophysiologic effects, and encouraging evidence of a drug effect in diabetic neuropathy and retinopathy has already been observed. In the large, controlled safety data base already available, the long-term clinical use of sorbinil is devoid of significant adverse effects in terms of both subjective side effects and laboratory parameters. The only clinically important adverse reaction reported to date has been a hypersensitivity reaction in the early weeks of therapy, which is similar to that seen with other hydantoins.
Pitts
N E
NE
Vreeland
F
F
Shaw
G L
GL
Peterson
M J
MJ
Mehta
D J
DJ
Collier
J
J
Gundersen
K
K
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy; D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D003929:Diabetic Neuropathies / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D004311:Double-Blind Method; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D048289:Imidazolidines; D010146:Pain / Q000188:drug therapy; D051381:Rats; D013012:Sorbitol / Q000097:blood; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*
D001786:Blood Glucose; D007093:Imidazoles; D048289:Imidazolidines; D013012:Sorbitol; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase; C026411:sorbinil